Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simmitinib vs Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT06656091Phase 3Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Cimetinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd.. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
Cimetinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06656091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656091.